Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis
Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value...
Gespeichert in:
Veröffentlicht in: | Vaccine 2012-07, Vol.30 (34), p.5086-5093 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 5093 |
---|---|
container_issue | 34 |
container_start_page | 5086 |
container_title | Vaccine |
container_volume | 30 |
creator | Agallou, Maria Smirlis, Despina Soteriadou, Ketty P Karagouni, Evdokia |
description | Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis. |
doi_str_mv | 10.1016/j.vaccine.2012.05.075 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1348487112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X12008274</els_id><sourcerecordid>1348487112</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</originalsourceid><addsrcrecordid>eNqNkkFv1DAQhS0EokvhJwA-ckkYO3bsXEBVBRRpJQ6liJvldSasl8TZ2smi_nuc7tIDFzjZh--9eZo3hLxkUDJg9dtdebDO-YAlB8ZLkCUo-YismFZVwSXTj8kKeC0KweD7GXmW0g4AZMWap-SMcwWi4WJFbr_du9jJj4H-8tOWrtGn7WCDt3Tr0zQGpFes2M99wpa2GNroJ--ow75P1I2hw5joPo4TunsTH-gwxxyMHnxyGG1P-wfL5NNz8qSz2ezF6T0nNx8_fL28KtZfPn2-vFgXTig1FR2veFcLyTmCkEoJ2yqFTcsQGmklaCdw03G90drmT1OjqhvbNFABCmZ5dU7eHH1zttsZ02SGJU_f24DjnAyrhBZaMfYfKHAhVM11nVF5RF0cU4rYmX30g413GTJLMWZnTsWYpRgD0uRisu7VacS8GbB9UP1pIgOvj0BnR2N_RJ_MzXV2kABMVByW0e-PBOatHTxGk5zH4LD1Me_etKP_Z4h3fzm43gfvbP8T7zDtxjmGXIlhJmWNuV7uZzkfxgE0V6L6DcaywLY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1024476286</pqid></control><display><type>article</type><title>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Agallou, Maria ; Smirlis, Despina ; Soteriadou, Ketty P ; Karagouni, Evdokia</creator><creatorcontrib>Agallou, Maria ; Smirlis, Despina ; Soteriadou, Ketty P ; Karagouni, Evdokia</creatorcontrib><description>Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2012.05.075</identifier><identifier>PMID: 22704924</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Antibodies, Protozoan - blood ; Antibodies, Protozoan - immunology ; Antibody Formation ; Antigens, Protozoan - immunology ; Bone Marrow Cells - cytology ; Cell Proliferation ; CpG ODNs ; DCs-based vaccine ; death ; dendritic cells ; Dendritic Cells - immunology ; Female ; Histone H1 ; histones ; Histones - administration & dosage ; Histones - immunology ; IFNγ ; IL-10 ; IL-12 ; Immunity, Cellular ; immunoglobulin G ; Immunoglobulin G - blood ; Injections, Intravenous ; Interferon-gamma - immunology ; interleukin-10 ; Interleukin-10 - immunology ; interleukin-12 ; Interleukin-12 - immunology ; interleukin-4 ; Interleukin-4 - immunology ; intravenous injection ; Leishmania ; Leishmania infantum ; Leishmania infantum - immunology ; Leishmania infantum - pathogenicity ; Leishmaniasis Vaccines - administration & dosage ; Leishmaniasis Vaccines - immunology ; Leishmaniasis, Visceral - immunology ; Leishmaniasis, Visceral - parasitology ; Leishmaniasis, Visceral - prevention & control ; Mice ; Mice, Inbred BALB C ; Murine visceral leishmaniasis ; oligodeoxyribonucleotides ; Oligonucleotides - immunology ; people ; Spleen - immunology ; Spleen - parasitology ; vaccination ; vaccine development ; vaccines ; visceral leishmaniasis</subject><ispartof>Vaccine, 2012-07, Vol.30 (34), p.5086-5093</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</citedby><cites>FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vaccine.2012.05.075$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64366</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22704924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agallou, Maria</creatorcontrib><creatorcontrib>Smirlis, Despina</creatorcontrib><creatorcontrib>Soteriadou, Ketty P</creatorcontrib><creatorcontrib>Karagouni, Evdokia</creatorcontrib><title>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Protozoan - blood</subject><subject>Antibodies, Protozoan - immunology</subject><subject>Antibody Formation</subject><subject>Antigens, Protozoan - immunology</subject><subject>Bone Marrow Cells - cytology</subject><subject>Cell Proliferation</subject><subject>CpG ODNs</subject><subject>DCs-based vaccine</subject><subject>death</subject><subject>dendritic cells</subject><subject>Dendritic Cells - immunology</subject><subject>Female</subject><subject>Histone H1</subject><subject>histones</subject><subject>Histones - administration & dosage</subject><subject>Histones - immunology</subject><subject>IFNγ</subject><subject>IL-10</subject><subject>IL-12</subject><subject>Immunity, Cellular</subject><subject>immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Injections, Intravenous</subject><subject>Interferon-gamma - immunology</subject><subject>interleukin-10</subject><subject>Interleukin-10 - immunology</subject><subject>interleukin-12</subject><subject>Interleukin-12 - immunology</subject><subject>interleukin-4</subject><subject>Interleukin-4 - immunology</subject><subject>intravenous injection</subject><subject>Leishmania</subject><subject>Leishmania infantum</subject><subject>Leishmania infantum - immunology</subject><subject>Leishmania infantum - pathogenicity</subject><subject>Leishmaniasis Vaccines - administration & dosage</subject><subject>Leishmaniasis Vaccines - immunology</subject><subject>Leishmaniasis, Visceral - immunology</subject><subject>Leishmaniasis, Visceral - parasitology</subject><subject>Leishmaniasis, Visceral - prevention & control</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Murine visceral leishmaniasis</subject><subject>oligodeoxyribonucleotides</subject><subject>Oligonucleotides - immunology</subject><subject>people</subject><subject>Spleen - immunology</subject><subject>Spleen - parasitology</subject><subject>vaccination</subject><subject>vaccine development</subject><subject>vaccines</subject><subject>visceral leishmaniasis</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkFv1DAQhS0EokvhJwA-ckkYO3bsXEBVBRRpJQ6liJvldSasl8TZ2smi_nuc7tIDFzjZh--9eZo3hLxkUDJg9dtdebDO-YAlB8ZLkCUo-YismFZVwSXTj8kKeC0KweD7GXmW0g4AZMWap-SMcwWi4WJFbr_du9jJj4H-8tOWrtGn7WCDt3Tr0zQGpFes2M99wpa2GNroJ--ow75P1I2hw5joPo4TunsTH-gwxxyMHnxyGG1P-wfL5NNz8qSz2ezF6T0nNx8_fL28KtZfPn2-vFgXTig1FR2veFcLyTmCkEoJ2yqFTcsQGmklaCdw03G90drmT1OjqhvbNFABCmZ5dU7eHH1zttsZ02SGJU_f24DjnAyrhBZaMfYfKHAhVM11nVF5RF0cU4rYmX30g413GTJLMWZnTsWYpRgD0uRisu7VacS8GbB9UP1pIgOvj0BnR2N_RJ_MzXV2kABMVByW0e-PBOatHTxGk5zH4LD1Me_etKP_Z4h3fzm43gfvbP8T7zDtxjmGXIlhJmWNuV7uZzkfxgE0V6L6DcaywLY</recordid><startdate>20120720</startdate><enddate>20120720</enddate><creator>Agallou, Maria</creator><creator>Smirlis, Despina</creator><creator>Soteriadou, Ketty P</creator><creator>Karagouni, Evdokia</creator><general>Elsevier Ltd</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>C1K</scope><scope>F1W</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope><scope>M7N</scope></search><sort><creationdate>20120720</creationdate><title>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</title><author>Agallou, Maria ; Smirlis, Despina ; Soteriadou, Ketty P ; Karagouni, Evdokia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Protozoan - blood</topic><topic>Antibodies, Protozoan - immunology</topic><topic>Antibody Formation</topic><topic>Antigens, Protozoan - immunology</topic><topic>Bone Marrow Cells - cytology</topic><topic>Cell Proliferation</topic><topic>CpG ODNs</topic><topic>DCs-based vaccine</topic><topic>death</topic><topic>dendritic cells</topic><topic>Dendritic Cells - immunology</topic><topic>Female</topic><topic>Histone H1</topic><topic>histones</topic><topic>Histones - administration & dosage</topic><topic>Histones - immunology</topic><topic>IFNγ</topic><topic>IL-10</topic><topic>IL-12</topic><topic>Immunity, Cellular</topic><topic>immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Injections, Intravenous</topic><topic>Interferon-gamma - immunology</topic><topic>interleukin-10</topic><topic>Interleukin-10 - immunology</topic><topic>interleukin-12</topic><topic>Interleukin-12 - immunology</topic><topic>interleukin-4</topic><topic>Interleukin-4 - immunology</topic><topic>intravenous injection</topic><topic>Leishmania</topic><topic>Leishmania infantum</topic><topic>Leishmania infantum - immunology</topic><topic>Leishmania infantum - pathogenicity</topic><topic>Leishmaniasis Vaccines - administration & dosage</topic><topic>Leishmaniasis Vaccines - immunology</topic><topic>Leishmaniasis, Visceral - immunology</topic><topic>Leishmaniasis, Visceral - parasitology</topic><topic>Leishmaniasis, Visceral - prevention & control</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Murine visceral leishmaniasis</topic><topic>oligodeoxyribonucleotides</topic><topic>Oligonucleotides - immunology</topic><topic>people</topic><topic>Spleen - immunology</topic><topic>Spleen - parasitology</topic><topic>vaccination</topic><topic>vaccine development</topic><topic>vaccines</topic><topic>visceral leishmaniasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agallou, Maria</creatorcontrib><creatorcontrib>Smirlis, Despina</creatorcontrib><creatorcontrib>Soteriadou, Ketty P</creatorcontrib><creatorcontrib>Karagouni, Evdokia</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agallou, Maria</au><au>Smirlis, Despina</au><au>Soteriadou, Ketty P</au><au>Karagouni, Evdokia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2012-07-20</date><risdate>2012</risdate><volume>30</volume><issue>34</issue><spage>5086</spage><epage>5093</epage><pages>5086-5093</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>22704924</pmid><doi>10.1016/j.vaccine.2012.05.075</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2012-07, Vol.30 (34), p.5086-5093 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_1348487112 |
source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
subjects | Allergy and Immunology Animals Antibodies, Protozoan - blood Antibodies, Protozoan - immunology Antibody Formation Antigens, Protozoan - immunology Bone Marrow Cells - cytology Cell Proliferation CpG ODNs DCs-based vaccine death dendritic cells Dendritic Cells - immunology Female Histone H1 histones Histones - administration & dosage Histones - immunology IFNγ IL-10 IL-12 Immunity, Cellular immunoglobulin G Immunoglobulin G - blood Injections, Intravenous Interferon-gamma - immunology interleukin-10 Interleukin-10 - immunology interleukin-12 Interleukin-12 - immunology interleukin-4 Interleukin-4 - immunology intravenous injection Leishmania Leishmania infantum Leishmania infantum - immunology Leishmania infantum - pathogenicity Leishmaniasis Vaccines - administration & dosage Leishmaniasis Vaccines - immunology Leishmaniasis, Visceral - immunology Leishmaniasis, Visceral - parasitology Leishmaniasis, Visceral - prevention & control Mice Mice, Inbred BALB C Murine visceral leishmaniasis oligodeoxyribonucleotides Oligonucleotides - immunology people Spleen - immunology Spleen - parasitology vaccination vaccine development vaccines visceral leishmaniasis |
title | Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A57%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20with%20Leishmania%20histone%20H1-pulsed%20dendritic%20cells%20confers%20protection%20in%20murine%20visceral%20leishmaniasis&rft.jtitle=Vaccine&rft.au=Agallou,%20Maria&rft.date=2012-07-20&rft.volume=30&rft.issue=34&rft.spage=5086&rft.epage=5093&rft.pages=5086-5093&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2012.05.075&rft_dat=%3Cproquest_cross%3E1348487112%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1024476286&rft_id=info:pmid/22704924&rft_els_id=1_s2_0_S0264410X12008274&rfr_iscdi=true |